TLR8 and neoplasm: In terms of modulating Treg cells for tumor immunotherapy via the TIR domain, TLR8 has been shown to reverse the immunosuppressive function of Tregs and enhance their anti-tumor activity by inhibiting glycolysis and glucose uptake (117, 118).